MODERN TRENDS FOR USE OF PROTECTED AMINOPENICILLINS IN THE TREATMENT OF RESPIRATORY TRACT INFECTIONS IN AMBULATORY PRACTICE
- Authors: Zharkova L.P.1, Stetsyuk O.U.1, Andreeva I.V.1, Egorova O.A.1, Zharkova LP1, Stetsyuk OU1, Andreeva IV1, Yegorova OA1
-
Affiliations:
- Issue: No 4 (2011)
- Pages: 8-16
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278807
- ID: 278807
Cite item
Full Text
Abstract
About the authors
Lyudmila Pavlovna Zharkova
Ol'ga Ul'yanovna Stetsyuk
Irina Veniaminovna Andreeva
Ol'ga Anatol'evna Egorova
L P Zharkova
O U Stetsyuk
I V Andreeva
O A Yegorova
References
- Чучалин А.Г., Синопальников А.И., Козлов Р.С. и др. Внебольничная пневмония у взрослых. Практические рекомендации по диагностике, лечению и профилактике. Пособие для врачей. МАКМАХ, 2010.
- Синопальников А.И., Козлов Р.С., Романовских А.Г. и др. Инфекционное обострение хронической обструктивной болезни легких. Практические рекомендации по диагностике, лечению, профилактике // Рос. мед. вести. 2006. № 11(1). C. 4-18.
- Snider GL. Nosology for our day: its application to chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167(5):678-83.
- Янов Ю.К., Рязанцев С.В., Страчунский Л.С. и др. Практические рекомендации по антибактериальной терапии синусита. Пособие для врачей // Клин. микробиол. антимикроб. химиотер. 2003. № 5(2). C. 167-74.
- Козлов Р.С. Пневмококки: уроки прошлого - взгляд в будущее. МАКМАХ. 2010.
- Hadley JA, Pfaller MA. Oral beta-lactams in the treatment of acute bacterial rhinosinusitis. Diagn Microbiol Infect Dis 2007;57(3):47-54.
- Dagan R, Leibovitz E. Bacterial eradication in the treatment of otitis media. Lancet Infect Dis 2002;2:593-604.
- Bronzwaer SL, Cars O, Buchholz U, et al. European Antimicrobial Resistance Surveillance System. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis 2002;8(3):278-82.
- Granizo JJ, Aguilar L, Casal J, et al. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and β-lactam consumption in Spain. J Antimicrob Chemother 2000;46:767-73.
- van de Sande-Bruinsma N, Grundmann H, Verloo D, et al. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis 2008;14(11):1722-30.
- Stetsiouk OU, Kozlov RS, Poupard JA, et al. Curbing pneumococcal resistance in orphanages: interventions on the basis of prospective surveillance of nasopharyngeal isolates. Clin Microbiol Infect 2006;12(S4):1484.
- Stratton CW. Dead bugs don't mutate: susceptibility isues in the emergence of bacterial resistance. Emerg Infect Dis [serial online] 2003 Jan [date cited]. Available from: URL: http://www.cdc.gov/ncidod/EID/vol9no1/02-0175.htm
- Решедько Г.К., Козлов Р.С. Состояние резистентности к антиинфекционным препаратам в России / Под редакцией Страчунский Л.С., Белоусов Ю.Б., Козлов С.Н. Практическое руководство по антиинфекционной химиотерапии. Смоленск, 2007. С. 32-46.
- European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2009. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC. 2010.
- Blasi F, Farrell DJ, Dubreuil L. Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired respiratory tract infections: the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin study year 5 (2003-004). Diagn Microbiol Infect Dis 2009;63(3):302-0.
- Анготоева И.Б. Острые риносинуситы. Как мы следуем стандартам. Материалы VII Конгресса российского общества ринологов "Актуальные вопросы ринологии на современном этапе". Таганрог, 2007.
- Nicolau DP. Pharmacodynamic optimization of β-lactams in the patient care setting. Critical Care 2008;2(4):2.
- Pavic-Sladoljev D. Patient compliance in the treatment of respiratory tract infections. K Lijec Vjesn 1997;119:193-200.
- Medeiros AA. Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. Clin Infect Dis 1997;24(1):19-45.
- White AR, Kaye C, Poupard J, et al. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother 2004;53(1):3-20.
- Auckenthaler R. Pharmacokinetics and pharmacodynamics of oral beta-lactam antibiotics as a two-dimensional approach to their efficacy. J Antimicrob Chemother 2002;50:13-7.
- Jacobs MR. How can we predict bacterial eradication? Int J Infect Dis 2003;7(1):13-20.
- File TM Jr, Benninger MS, Jacobs MR. Evolution of amoxicillin/clavulanate in the treatment of adults with acute bacterial rhinosinusitis and community-acquired pneumonia in response to antimicrobial-resistance patterns. Clin Lab Med 2004;24(2):531-51.
- Kaye CM, Allen A, Perry S, et al. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate. Clin Ther 2001;23(4):578-84.
- Garau J. Performance in practice: bacteriological efficacy in patients with drug-resistant Streptococcus pneumoniae. Clin Microbiol Infect 2003;9(1):28. Abstract S167.
- Sethi S, Breton J, Wynne B. Efficacy and safety of pharmacokinetically enhanced amoxicillin/clavulanate (AMX/CA) 2000/125 mg b.i.d. for 5 days vs AMX/CA 875/125 mg b.i.d. for 7 days in the treatment of acute exacerbations of chronic bronchitis (AECB). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract L-1592. P. 427.
- Richard MP, Wynne B, et al. Clinical safety of pharmacokinetically enhanced amoxicillin/ clavulanate compared with currently approved formulations of amoxicillin/clavulanate. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001. Abstract 952. Р. 25.
- File T, Lode H, Kurz H, et al. Comparative efficacy/safety of pharmacokinetically enhanced amoxicillin/clavulanate 2000/125 mg vs amoxicillin/clavulanate 875/125 mg in community-acquired pneumonia (CAP). 99th International Conference of the American Thoracic Society, Seattle, WA, 2003. Abstract B11. P. A370.
- Rosenfeld RM, Andes D, Bhattacharyya N, et al. Clinical practice guideline: adult sinusitis. Otolaryngol Head Neck Surg 2007;137 (3):1-31.
- World Health Organization. WHO Model Prescribing Information. Drugs used in Bacterial Infections. 2001. WHO, Geneva, Switzerland.
- Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/ American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(2):27-72.
- American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media. Diagnosis and management of acute otitis media. Pediatrics 2004;113(5):1451-65.
- Augmentin XR, prescribing information. GlaxoSmithKline, Research Triangle Park, NC, USA, 2002.
- File TM Jr, Jacobs MR, Poole MD, Wynne B. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate. Int J Antimicrob Agents 2002;20(4):235-47.
- Anon JB, Berkowitz E, Breton J, et al. Efficacy/safety of amoxicillin/ clavulanate in adults with bacterial rhinosinusitis. Am J Otolaryngol 2006;27(4):248-54.
- Garau J, Twynholm M, Garcia-Mendez E, et al. Comparative efficacy and safety of pharmacokinetically enhanced amoxicillin/clavulanate 2000/125 mg b.d. versus amoxicillin/ clavulanate 875/125 mg t.d.s. in community-acquired pneumonia (CAP). 12th European Congress of Clinical Microbiology and Infectious Diseases. Milan, Italy, April 24-27, 2002.
- Petitpretz P, Chidiac C, Soriano F, et al. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults. Int J Antimicrob Agents 2002;20(2):119-29.
- Каманин Е.И., Стецюк О.У. Инфекции верхних дыхательных путей и ЛОР-органов / Под редакцией Страчунский Л.С., Белоусов Ю.Б., Козлов С.Н. Антибактериальная терапия. Практическое руководство. М., 2000.
- Andes D, Anon J, Jacobs MR, et al. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Clin Lab Med 2004;24(2):477-502.
Supplementary files
![](/img/style/loading.gif)